🧠 Understanding Normal Pressure Hydrocephalus

Normal Pressure Hydrocephalus (NPH) is a treatable brain disorder primarily affecting adults over the age of 60, characterized by an abnormal buildup of cerebrospinal fluid (CSF) in the brain's ventricles despite normal pressure levels. This excess fluid stretches the ventricles, leading to pressure on surrounding brain tissue and disrupting normal function. Unlike other forms of hydrocephalus that involve high pressure, NPH presents a unique challenge because its symptoms often mimic more common conditions like Alzheimer's disease, Parkinson's disease, or even normal aging.

The classic triad of NPH symptoms includes gait disturbance, cognitive impairment, and urinary incontinence. Gait issues typically manifest as a 'magnetic' or shuffling walk where patients have difficulty initiating steps and turning, often described as if their feet are stuck to the floor. Cognitive problems involve slowed thinking, memory lapses, and executive dysfunction, resembling dementia but potentially reversible with treatment. Urinary symptoms start with urgency and frequency, progressing to incontinence.

• Gait disturbance: Difficulty walking, broad-based unsteady steps, falls risk.
• Cognitive impairment: Apathy, reduced attention, bradyphrenia (slowed mental processing).
• Urinary incontinence: Initial urgency leading to loss of bladder control.

Prevalence estimates suggest around 800,000 Americans over 60 may have NPH, yet over 80% remain undiagnosed or untreated, according to the Hydrocephalus Association. Diagnosis involves clinical evaluation, brain imaging showing ventriculomegaly (enlarged ventricles) disproportionate to cortical atrophy, and often a lumbar puncture (LP) tap test where removing CSF temporarily improves symptoms, confirming shunt-responsiveness.

Without intervention, NPH progresses, leading to severe disability, nursing home placement, or shortened lifespan. Early recognition is crucial as it is one of the few reversible causes of dementia.

Challenges with Traditional NPH Treatments

The gold standard treatment for NPH has been the ventriculoperitoneal (VP) shunt for over 60 years. This surgical procedure involves drilling a hole in the skull to place a catheter into the brain's ventricle, connected to a valve that regulates CSF flow, tunneling under the skin to the abdomen where fluid is absorbed.

While effective in many cases—up to 80% show improvement in gait post-shunt—the VP shunt carries significant risks. Complication rates are high: infections occur in 5-10% of cases, often requiring shunt removal and antibiotics; mechanical failure or obstruction affects 40-50% within two years, necessitating revisions; over-drainage can cause subdural hematomas; and average hospital stays are around three days.

• Infection risk: 5-10%, higher in elderly with comorbidities.
• Malfunction/revision: Nearly 50% at two years.
• Over-drainage/hemorrhage: Subdural collections in up to 10%.
• Procedure-related morbidity: Craniotomy, general anesthesia, abdominal surgery.

These issues deter many patients, especially frail elderly with comorbidities, leaving thousands untreated. Researchers and clinicians have long sought a safer, less invasive alternative.

Introducing the eShunt System: A Game-Changing Approach

The eShunt System, developed by CereVasc, Inc., represents the first major innovation in communicating hydrocephalus treatment since the VP shunt. This endovascular device is implanted entirely through blood vessels, avoiding craniotomy or abdominal incision.

Performed by interventional neuroradiologists or neurosurgeons, the procedure begins with access via the femoral vein in the groin. Under fluoroscopy guidance, a catheter navigates to the jugular vein and superior sagittal sinus (a large vein on the brain's surface). A specialized delivery system punctures the dura (brain covering) to access the subarachnoid CSF space at the skull base, deploying a self-expanding stent-valve that allows one-way CSF drainage into the venous sinus for natural reabsorption.

The entire implantation takes about one hour, often under local anesthesia with sedation, enabling same-day or next-day discharge. No head shaving, burr holes, or programmable valves needed initially.

This minimally invasive nature expands eligibility to patients previously deemed high-risk for open surgery, potentially transforming NPH care.

📊 CereVasc's Multi-Center Study Delivers Striking Results

In a landmark prospective, multi-center, single-arm study published in the Journal of NeuroInterventional Surgery, CereVasc reported outcomes from 66 patients treated with the eShunt System across 12 sites in the US and Argentina. Patients, averaging elderly with confirmed NPH, underwent implantation and 90-day follow-up.

Primary efficacy: 95% of participants (61 out of 64 evaluable) showed improvement in at least one core NPH symptom—gait disturbance (measured by Timed Up and Go test), cognitive function (Montreal Cognitive Assessment), or urinary symptoms (Neurogenic Bladder Symptom Score). Statistically significant gains occurred across all three domains from baseline.

• Gait: Marked reduction in TUG times, improved mobility.
• Cognition: MoCA score increases, better daily functioning.
• Urinary: Reduced NBSS scores, continence restoration.

Building on a prior US pilot study (NCT05232838) at 11 academic centers where 97% (29/30) improved with zero device-related serious adverse events (SAEs) and 1.3-day hospital stays, this larger dataset reinforces efficacy.

For more details, see the study announcement.

Safety Profile Outshines Traditional Methods

Safety was exemplary: 0% device-related SAEs; 3% procedure-related SAEs (all resolved non-surgically); zero infections, cerebral hemorrhages, or over-drainage (confirmed by independent core lab MRI/CT review). This contrasts sharply with VP shunts' 25% 30-day complication/readmission rates.

In the US pilot, no unanticipated adverse device effects occurred, highlighting the endovascular route's advantages: reduced infection via no skin tunnel/abdomen, precise valve sizing, physiologic drainage.

Longer-term data from one-year follow-ups in earlier cohorts show sustained improvements, fueling optimism. Experts note this profile could slash revision surgeries, a major VP shunt burden.

Explore clinical trial data at ClinicalTrials.gov.

Expert Perspectives on the eShunt Breakthrough

Dr. Charles Matouk, Vice Chair of Neurosurgery at Yale School of Medicine and a lead investigator, stated: "The favorable safety profile, along with statistically significant symptom improvements at 90 days, provides an early clinical signal supporting endovascular NPH treatment." Yale, the top US enrolling site with 19 implants, praises its feasibility.

Dr. Pedro Lylyk, ENERI CEO, added: "Conventional shunting has documented risks; these results suggest fewer complications while improving symptoms."

CereVasc CEO Dan Levangie emphasized: "The eShunt is a significant advancement; STRIDE will compare it head-to-head with VP shunts."

Patients report rapid gains: better walking within days, sharper thinking, dignity restored—life-changing for families.

Learn more from Yale experts: Yale Medicine on eShunt.

The Road Ahead: STRIDE Pivotal Trial

Enrolling at 28 sites across the US, Argentina, and Canada, the STRIDE trial (randomized controlled) pits eShunt against VP shunt in NPH patients. As the first direct comparison, positive results could support FDA approval, establishing eShunt as a new standard.

Over 100 patients treated to date across studies, with Gen2 device refinements enhancing precision. Expansion to pediatrics (FDA Breakthrough Designation) hints at broader applications.

Visit STRIDE trial site for eligibility.

Photo by Abdulai Sayni on Unsplash

Transforming Lives: Implications for NPH Patients

The eShunt's 95% success rate heralds hope for millions undiagnosed with NPH. By minimizing risks, it encourages earlier intervention, potentially averting irreversible damage. For researchers in neurology and neurosurgery, it opens doors to endovascular therapies for other CSF disorders.

Academic institutions drive this progress—Yale, VCU Health, and others lead trials. Aspiring professionals can pursue research jobs or clinical research jobs in neuro innovation. Explore higher ed jobs in medicine or professor jobs at top universities advancing such tech.

Share experiences on Rate My Professor or check higher ed career advice for neurology paths. Visit university jobs and higher-ed-jobs for opportunities. Institutions posting openings can use our platform to connect with talent.

This publication underscores research's impact—stay informed via AcademicJobs.com for the latest in higher education and medical breakthroughs.